• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 15th March 2023

Around The World in HTAs: Spain – Are We There Yet?

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.

Pat-1-scaled-1
Patricia Cubi-Molla
20201112_110035
Laura Vallejo-Torres
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Air balloon HTA v4

The health system in the country

Spain has a universal national health system (NHS) mainly funded by taxes. The Spanish NHS is organised in two levels, national (represented by the Spanish Ministry of Health, MoH) and regional (represented by the regional MoH in each of the 17 autonomous communities in Spain). An Interterritorial Council (CISNS, Spanish acronym) is the governance body that makes the final decision about market access to new health technologies at a national level. The CISNS comprises the Health Minister of Spain plus the highest hierarchy level of the 17 regional MoHs. Further details of the Spanish health system can be found in the series of Health Systems in Transition.

A roadmap for new technologies

There are two separate health technology assessment (HTA) processes: one for medicines, and one for other health technologies (such as medical devices).

Assessment of other health technologies

RedETS is the acronym for the Spanish Network of Agencies for Assessing National Health System Technologies and Performance. When a new non-drug health technology seeks access to the Spanish NHS, a commission (led by the Spanish MoH and with regional authorities’ participation) requests RedETS to produce a report, which usually includes an economic evaluation of the new technology. RedETS follows the paper by Lopez-Bastida et al. (2010) as a reference methods guideline for economic evaluations. The commission receives the report from RedETS, assesses the intervention, and makes a recommendation to the CISNS, i.e. the inter-regional Spanish council (CISNS), which makes the final decisions that are then formally adopted and implemented by the MoH.

Assessment of medicines

After the European Medicines Agency marketing authorisation or approval, a government commission (CIPM, Spanish Acronym), with representatives from the Spanish MoH, other national ministries, and regional governments, is the decision-maker for reimbursement of new medicines. The primary input for CIPM’s decisions is provided by the Spanish HTA agency for pharmaceuticals (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS).

This primary input takes the form of the so-called therapeutic positioning reports (“Informe de Posicionamiento Terapeutico” or IPT). IPTs were created in 2013 to inform Spanish MoH’s decisions about the value and access to new technologies and included the evaluation of clinical effectiveness and safety; since 2020, IPTs are supposed to incorporate an economic evaluation of the new drug, although the percentage of IPTs currently including economic evaluations remains low. The Spanish Network for the Economic Evaluation of medicines (REvalMed, Spanish Acronym) follows the methods guideline created in 2017 by the GENESIS group (part of the Spanish hospital pharmacy association (Sociedad Española de Farmacia Hospitalaria, SEFH).

The CIPM decides on the reimbursement of the new drug with input from AEMPS. AEMPS also suggests a price for the drug, which is discussed by the CIPM.

Current challenges

The standard process to evaluate pharmaceutical products gives a narrow time window of 10 days for REvalMed to conduct the economic evaluation of the new drug, which can have an impact on the quality of the assessment. In addition, the composition of REvalMed is controversial: only two out of 143 experts are health economists. REvalMed has recently reached out for some external experts in economic evaluations, but it is unclear how the provision will be addressed. Increasing the participation of patients as active stakeholders is another aspect that has been raised.
The methods guidelines in use have been criticised, as they are not considered complete from a health economic perspective (for instance, it does not include clear recommendations about the modelling). Overall, there is also a general agreement that the process has to be updated.

Next steps for the Spanish HTA

The Royal-Decree Law (passed in 2012) that required that economic evaluations and budget impact analyses should be taken into account represented the seeds for a healthy HTA process in Spain. Through the introduction of economic evaluations in the IPTs, and the creation of REvalMed, the Spanish Government is watering those seeds for a promising HTA process to grow. For Spain to crop a healthy HTA system, and with a long-term view, we envisage two main steps.

The first step is to consolidate the process. For this purpose, it is essential that the Government incorporates the provision of an independent body that can carry out the appraisal process and act as a referee of the economic evaluation (which is not a new claim, see for example our blog about ‘HispaNICE’)

The second step is to identify the long-term objectives and to design a road map towards it. This could allow the Spanish system, still in its initial stages, to learn from the mistakes of the well-established HTA systems and address the limitations that have been repeatedly flagged in those. For example, we can think of moving to a framework that incorporates outcome measures beyond health or health-related quality of life, such as wellbeing; to incorporate treatment effects that fall outside the healthcare sector; and to incorporate distributional considerations that can reflect equity aspects. Those steps probably pull in opposite directions, but both are attainable.

Citations

Bernal-Delgado E, García-Armesto S, Oliva J, Sánchez Martínez FI, Repullo JR, Peña-Longobardo LM, Ridao-López M, Hernández-Quevedo C. Spain: Health system review. Health Systems in Transition, 2018;20(2):1–179. Pages 21-22

López-Bastida, J., Oliva, J., Antonanzas, F., García-Altés, A., Gisbert, R., Mar, J. and Puig-Junoy, J., 2010. Spanish recommendations on economic evaluation of health technologies. The European Journal of Health Economics, 11(5), pp.513-520.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • HTA

Related Insights

G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
jacek-dylag-IiQXLbTTQCw-unsplash-scaled-1
  • Insight
  • December 2022

ISPOR Europe Round-up: “Gene Therapies: Where High Promise Meets High Uncertainty, How Should HTA Methodologies Appropriately Value and Enable Access?”

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
  • Insight
  • February 2021

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!